RHB-105 is an antibiotics and proton pump inhibitor (PPI) proprietary drug combination for Helicobacter pylori (H. pylori) infection. RHB-105 was acquired from Sydney-based Giaconda [ASX: GIA] in August 2010.
RHB-105 is an antibiotics and PPI combination planned to be indicated for the treatment of H. pylori infections, a major cause of chronic gastritis, peptic ulcer disease, gastric cancer and mucosa associated lymphoid tissue (MALT) lymphoma.
In October 2013 RedHill initiated the ERADICATE Hp study – a randomized, double-blind, placebo-controlled Phase III study to evaluate the safety and efficacy of RHB-105 as a first line therapy for H. pylori infection.
Initiation of the Phase III study follows favorable results in a phase II study conducted in Australia, FDA acceptance of the Company’s IND application and Institutional Review Board (IRB) approval.